Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study to Investigate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of the Human GATA-3-specific DNAzyme Solution SB010 in Patients With Mild Allergic Asthma. A Randomised, Double-blind, Parallel, Multicentre, Phase-IIa Study

NCT01743768 is registered in ClinicalTrials.gov with Sterna Biologicals GmbH & Co. KG as lead sponsor.

NCT NCT01743768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01743768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study to Investigate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of the Human GATA-3-specific DNAzyme Solution SB010 in Patients With Mild Allergic Asthma. A Randomised, Double-blind, Parallel, Multicentre, Phase-IIa Study
Lead sponsor
Sterna Biologicals GmbH & Co. KG
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
December 31, 2013
Enrollment
38 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

asthma